Trastuzumab biosimilar (Alteogen)

曲妥珠单抗生物类似药（齐鲁制药）

Report date: 2024/07/05 16:43:35

Base Information

Drug NameTrastuzumab biosimilar (Alteogen)
Drug Alias Name重组抗HER2人源化单抗（齐鲁制药）Trastuzumab (Alteogen)Trastuzumab biosimilar (Alteogen/Cristalia/Qilu Pharmaceutical)群司珠单抗生物仿制药（齐鲁制药）Recombinant humanized anti-HER2 antibody (Qilu Pharma) +[12] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsMetastatic breast cancerStomach NeoplasmsEsophageal Neoplasms +[4] 
Global Approved IndicationsBreast Neoplasms
Approved Indications in ChinaBreast Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2024/06/28
Country/TerritoryCanadaUnited StatesPuerto Rico +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAlteogen Inc
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteQilu Pharmaceutical Co Ltd
Inactive CompaniesAlteogen Inc
Active IndicationsBreast Neoplasms
Inactive IndicationsMetastatic breast cancerStomach NeoplasmsEsophageal Neoplasms

Other Information

ATC CodeL01XC03
Related LinksN/A